198 related articles for article (PubMed ID: 27889876)
1. Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats.
Kobuchi S; Ito Y; Sakaeda T
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):707-718. PubMed ID: 27889876
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
[TBL] [Abstract][Full Text] [Related]
4. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
5. Semi-physiological pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats.
Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
Xenobiotica; 2015 Jan; 45(1):19-28. PubMed ID: 25050790
[TBL] [Abstract][Full Text] [Related]
6. Semi-physiological pharmacokinetic-pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats.
Kobuchi S; Ito Y; Hayakawa T; Kuwano S; Baba A; Shinohara K; Nishimura A; Shibata N; Takada K
Xenobiotica; 2014 Sep; 44(9):804-18. PubMed ID: 24650147
[TBL] [Abstract][Full Text] [Related]
7. Nonlinear pharmacokinetics of 5-fluorouracil in rats.
Jarugula VR; Lam SS; Boudinot FD
J Pharm Sci; 1997 Jun; 86(6):756-8. PubMed ID: 9188061
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer.
Kobuchi S; Ito Y; Okada K; Imoto K; Kuwano S; Takada K
J Pharm Sci; 2013 Jun; 102(6):2056-2067. PubMed ID: 23592368
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
10. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
12. Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats.
Simonsen LE; Wählby U; Sandström M; Freijs A; Karlsson MO
Anticancer Res; 2000; 20(3A):1519-25. PubMed ID: 10928065
[TBL] [Abstract][Full Text] [Related]
13. Effects of levofolinate calcium on subacute intravenous toxicity of 5-fluorouracil in rats.
Murakami Y; Fujii H; Ichimura A; Murata A; Yamashita N; Takagi H; Tauchi K
J Toxicol Sci; 1998 May; 23 Suppl 1():11-29. PubMed ID: 9617733
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients.
Casale F; Canaparo R; Serpe L; Muntoni E; Pepa CD; Costa M; Mairone L; Zara GP; Fornari G; Eandi M
Pharmacol Res; 2004 Aug; 50(2):173-9. PubMed ID: 15177306
[TBL] [Abstract][Full Text] [Related]
15. [Relationship of plasma concentration of 5-fluorouracil with toxicity and response in patients with nasopharyngeal carcinoma].
Yu GS; He YJ; Liao H; Li S
Ai Zheng; 2003 Dec; 22(12):1349-51. PubMed ID: 14693067
[TBL] [Abstract][Full Text] [Related]
16. A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.
Kobuchi S; Tsuda M; Okamura M; Nakamura T; Ito Y
Anticancer Res; 2023 Mar; 43(3):1121-1130. PubMed ID: 36854515
[TBL] [Abstract][Full Text] [Related]
17. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.
Friberg LE; Freijs A; Sandström M; Karlsson MO
J Pharmacol Exp Ther; 2000 Nov; 295(2):734-40. PubMed ID: 11046112
[TBL] [Abstract][Full Text] [Related]
18. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.
van Kuilenburg AB; Maring JG
Pharmacogenomics; 2013 May; 14(7):799-811. PubMed ID: 23651027
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
